CINV Existing and Pipeline Drugs Market to reach US$ 3.2 billion in 2031, expanding at a CAGR of 5.8%: TMR Report

A significant portion of current research and development efforts, higher federal healthcare funding, and a growing geriatric cancer incidence are some of the drivers propelling the global CINV existing and pipeline drugs market.Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) -- In 2021, the global CINV existing and pipeline drugs market was estimated to be worth US$ 1.9 billion. It is expected to increase at a 5.8% CAGR from 2022 to 2031. The global market for CINV existing

Related Keywords

Canada ,Delaware ,United States ,India ,China ,America ,American ,Asia Pacific ,Aloxi Palonosetron ,Akynzeo Netupitant Palonosetron ,Nikhil Sawlani ,Premium Research Report ,Merck Co Inc ,Transparency Market Research ,Tesaro Inc ,Heron Therapeutics Inc ,Glaxosmithkline ,World Health Organization ,Transparency Market Research Inc ,Helsinn Holding ,Report Sample ,Gain Comprehensive Insights ,North American ,Ask For ,Custom Report ,Pipeline Drugs Market ,Prominent Drivers ,Market Research ,Pipeline Drugs ,Heron Therapeutics ,Get Your Copy ,Extended Release Granisetron Injection ,Canada Toll Free ,Global Market ,Wilmington ,Ginv ,North America ,Market Report ,Dancer ,